Bluebrando, LC is giving us plenty of clues as to how effective their products are. That presentation highlighted trial expansion into new cancers. This is a lot of work and cost. She would not be going to this effort if she wasn’t seeing great data that justifies it.
The same goes for ODD and FT designation. She’s seeing the data to support the planning. In fact this application must have already been submitted prior to the release of the presentation!
And note the OBD in Sept this year followed by PH2 in Late October. So the planning and paperwork is well underway. Again what they are seeing justifies the planning and expense.
So the question shareholders need to ask themselves, do they want to be sitting on the sidelines when ph1B Vaxinia is finished and early Oncarlytics data is also public knowledge.
IMU Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)